bexarotene has been researched along with Thyroid Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JY; Chi, CW; Hsu, YC; Lee, CH; Lee, HC; Wang, JJ | 1 |
| French, J; Haugen, B; Jimeno, A; Kane, M; Klopper, J; Pike, L; Sams, S; Tompkins, K | 1 |
| Balitrand, N; Boelle, PY; Cassinat, B; Chomienne, C; Cras, A; Darsin-Bettinger, D; Politis, B; Toubert, ME | 1 |
| Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
| Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Visser, TJ | 1 |
| Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
| Berenz, A; Bissonnette, RP; Haugen, BR; Hays, WR; Janssen, J; Klopper, JP; Pugazhenthi, U; Sharma, V; Singh, M | 1 |
5 trial(s) available for bexarotene and Thyroid Neoplasms
| Article | Year |
|---|---|
A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.
Topics: Adenocarcinoma, Follicular; Aged; Anticarcinogenic Agents; Bexarotene; Carcinoma, Papillary; Female; Humans; Male; Middle Aged; Tetrahydronaphthalenes; Thyroid Neoplasms; Treatment Outcome | 2015 |
Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
Topics: Antigens, Differentiation; Antineoplastic Agents; Bexarotene; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; E1A-Associated p300 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Isotretinoin; Male; Middle Aged; Neoplasm Invasiveness; NF-kappa B; Receptors, Retinoic Acid; Retinoid X Receptor gamma; Tetrahydronaphthalenes; Thyroid Neoplasms; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tretinoin | 2012 |
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Bexarotene; Carcinoma, Papillary; Cell Differentiation; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2006 |
Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Drug Evaluation, Preclinical; Female; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Hormones; Thyroid Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine | 2007 |
Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Anticarcinogenic Agents; Bexarotene; Combined Modality Therapy; Disease Progression; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Tetrahydronaphthalenes; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
2 other study(ies) available for bexarotene and Thyroid Neoplasms
| Article | Year |
|---|---|
Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
Topics: Bexarotene; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Humans; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Symporters; Thyroid Neoplasms; Tumor Hypoxia | 2020 |
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
Topics: Animals; Antineoplastic Agents; Bexarotene; Carcinoma; Cell Line, Tumor; Humans; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2008 |